Shares of Beijing Chunlizhengda Medical Instruments Co., Ltd. (Stock Code: 01858) surged 6.20% in Friday's trading session, following the release of impressive third-quarter results and the announcement of a dividend payout.

The medical instruments manufacturer reported a substantial 48.75% year-on-year increase in revenue, reaching RMB756.09 million for the first nine months of 2025. Net profit attributable to shareholders skyrocketed by 213.21% to RMB191.53 million. The company's third-quarter performance was particularly strong, with revenue soaring 109.51% compared to the same period last year. Chunlizhengda attributed its success to a strategic focus on product innovation, international development, and improved operational management.

Adding to investor optimism, the company announced a third-quarter dividend of RMB2.10 (tax inclusive) for every 10 shares, subject to approval at an upcoming extraordinary general meeting. The dividend is expected to be paid on or before January 19, 2026. Furthermore, Chunlizhengda proposed several corporate governance changes, including the abolishment of its Supervisory Committee, which may have contributed to positive market sentiment. These factors combined likely drove the significant stock price increase, reflecting investor confidence in the company's financial performance and shareholder value creation.